Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor,
in combination with pembrolizumab in patients with advanced solid tumors with a known STK11
mutation.
The main question[s] it aims to answer are:
- the recommended dose for Phase 2
- to evaluate the safety and tolerability of the combination therapy
- to determine the pharmacokinetics of TNG260
- to evaluate the initial antineoplastic activity
Participants will receive study treatment until they experience an undesirable side effect,
their disease progresses or until they withdraw consent.